Encouraging Patient Survival Observations Reported in Ovarian Cancer Lira-cel CAR-T Trial; Achieves Regulatory Approval Enabling Major Dose Escalation February 17, 2026
Patient recruitment opened for Ph 1 trial of Innocell in patients with recurrent epithelial ovarian cancer February 9, 2026
Positive Results from Ph 1b/2 PESCO Trial of MVP-S, Keytruda and Cyclophosphamide in Recurrent Epithelial Ovarian Cancer (EOC) Reported February 1, 2026
Positive Results from Ph 1B/2 PESCO Trial of MVP-S with Keytruda and Low-Dose Cyclophosphamide for Patients with Recurrent Epithelial Ovarian Cancer (EOC) Announced January 25, 2026
OS Primary Endpoint Met in Pivotal Ph 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer January 25, 2026
Sofetabart mipitecan receives US FDA Breakthrough Therapy designation for the treatment of certain patients with platinum-resistant ovarian cancer January 25, 2026
Vigil Demonstrates Significant Survival Benefit in cTMB-H/HRP Ovarian Cancer Patients; Ph 2b VITAL Trial Analysis Published in JCO – Precision Oncology January 18, 2026
Promising Data from Ongoing Ph 2a study for BI-1808 with KEYTRUDA in Recurrent Ovarian Cancer Reported January 11, 2026
Positive ACR-368 Ph 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840 Data Announces January 11, 2026
Successful Pre-IND FDA Meeting and Continued Progress Toward First-in-Human Trial of ERNA-101 in Ovarian Cancer Announced January 11, 2026
FDA Fast Track Designation for ETX-19477 for BRCA-Mutated, Platinum-Resistant Ovarian Cancer Patients Announced January 11, 2026
Data Reported from Ongoing Ph 2a study for BI-1808 with KEYTRUDA in Recurrent Ovarian Cancer January 4, 2026
LIXTE Biotechnology, The University of Texas MD Anderson Cancer Center, and GSK expand collaboration on LB-100 to treat ovarian clear cell cancer December 30, 2025
Results from Ph 2 POC study of HLX43 in recurrent/metastatic cervical cancer published December 9, 2025
DESTINY-Ovarian01 Ph 3 Trial of ENHERTU® Initiated as 1L Maintenance Therapy in Patients with HER2 Expressing Advanced Ovarian Cancer December 9, 2025
Tubulis announces Series C funding of €344M (US $401M) to initiate pivotal trials with lead ADC candidate TUB-040 November 4, 2025
Ph 2 study of BND-22 (SAR444881) + anti-PD-1 therapy in IO-refractory NSCLC or IO-naive MSS-CRC or ovarian cancer to be initiated October 16, 2025
Anaptys Announces Intent to Separate Biopharma Operations from Substantial Royalty Assets by Year-end 2026 October 7, 2025
